发信人: qqjjpp119 (), 信区: JobMarket
标 题: 无锡药明生物质量控制部人才招聘
关键字: 生物制药 药物分析 质量控制
发信站: BBS 未名空间站 (Thu Aug 12 11:35:24 2021, 美东)
With high demand of talents to commensurate with the rapid growth of the
company, we are seeking highly motivated and accomplished Directors of
Quality Control in WuXi Biologics China.
Essential Roles and Responsibilities
• Serve as a competent Analytical Expert and/or Leader in quality
analytics, bioassay, or microbial contamination control and monitoring of
bio-therapeutic products, internally, and to collaborate with partners/
stakeholders and the drug regulatory agencies to ensure WuXi Biologics is
appropriately represented in technical and compliance matters.
• Write, review and approve technical documents including but not
limited to standard operational procedures, analytical methods,
qualification/validation protocols and reports.
• Manage QC related projects and customer relationship maintenance.
• Lead audit preparation and response to the findings of customers
and drug administration departments. Author/review QC related sections in
• Work closely with the Sr. management team to drive continuous
improvement of technical excellence, quality and efficiency of QC operation.
• M.S / Ph.D. in Analytical Chemistry, Biochemistry, Microbiology,
Biology, Molecular Biology, Biological Engineering, or related field.
• Good computer operation skill, intermediate level in Microsoft
Word, Excel, PowerPoint etc. Strong communication skills in English and
Chinese (English is a minimum requirement), fluent in speaking, writing and
reading in both languages. Critical thinking, proactive working attitude,
scientific reasoning and problem solving skills.
If interested, please contact Ms. Phoenix Wu ([email protected]
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a
leading global open-access biologics technology platform offering end-to-end
solutions to empower organizations to discover, develop, and manufacture
biologics from concept to commercial manufacturing. The company’s history
and achievements demonstrate its commitment to providing a truly ONE-stop
service offering and strong value proposition to its global clients. As of
March 22, 2021, there were a total of 361 integrated projects, including 190
projects in pre-clinical development stage, 137 projects in early-phase (
phase I and II) clinical development, 32 projects in late-phase (phase III)
development and 2 projects in commercial manufacturing. With total estimated
capacity for biopharmaceutical production planned in China, Ireland, the U.
S., Germany, and Singapore around 430,000 liters after 2024, WuXi Biologics
will provide its
※ 来源:·WWW 未名空间站 网址：mitbbs.com 移动：在应用商店搜索未名空间·[FROM: 98.]